Hoth Therapeutics Stock Rallies As Lead Peptide Candidate Shows Encouraging Preclinical Antiviral Activity Against COVID-19

by Vandana Singh, Benzinga Editor

March 23, 2021 8:27 AM | 1 min read | Make a Comment

Hoth Therapeutics Inc HOTH soars after reporting new in vitro data for its lead peptide candidate for HT-002 to treat COVID-19.
Data showed that HT-002 inhibited 50% of the cytopathic effect (CPE) of the SARS-CoV-2 virus at 61.7 µM (the EC50). No cytotoxicity was demonstrated at concentrations of up to 200 µM of the peptide.
Hoth plans to pursue further preclinical animal studies to support the lead peptide's therapeutic potential and investigate the route of administration.
Price Action: HOTH shares are trading higher by 55% at $3.42 in premarket trading on the last check Tuesday.

Posted In: Biotech News Penny Stocks Health Care FDA General Covid-19

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.